Retatrutide: Eli Lilly’s Triple-Target Breakthrough in Metabolic Disease Therapy
Revolutionizing Obesity and Diabetes Treatment with Unmatched Efficacy Core Innovations and Mechanism of Action Triple-Receptor Agonist Design Retatrutide (LY3437943) is the world’s first GLP-1R/GIPR/GCGR triple agonist, engineered to simultaneously activate: GLP-1 Receptor: Suppresses appetite, delays gastric emptying, and enhances insulin secretion. GIP Receptor: Boosts insulin sensitivity and regulates lipid metabolism. Glucagon Receptor (GCGR): Promotes […]